medigraphic.com

2005, Number S1

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2005; 43 (S1)

Hemophiliacs with inhibitors: How to manage them?

Vallin AS

Language: English
References: 16
Page: 143-145
PDF size: 108.79 Kb.


Text Extraction

Inhibitors are antibodies that neutralize factor VIII or IX. It is considered as one of the most severe and important complication of hemophilia treatment. Although many clinical and laboratory efforts are being done on this field, still generates higher morbidity and mortality, due to the poor control of bleeding with standard treatment.
The inhibitor incidence in hemophilia A is 20-30 %, most of them occurring in severely affected patients, and in hemophilia B is 4 %.1


REFERENCES

  1. Kasper CK. Diagnosis and management of inhibitors to Factor VIII and IX. An introductory Discussion for Physicians. Treatment of Hemophilia Monograph Series, N0 34. World Federation of Hemophilia; September 2004. Available at: http://www.wfh.org/Content_Documents/TOH-Monographs/TOH-34_English_Inhibitors.pdf. Accessed August 1st, 2005.

  2. Dimichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-287.

  3. UKHCDO. Guideline. The diagnosis and manage-ment of Factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors’ Organi-zation. Br J Haematol 2001;111:78-90.

  4. Leissinger CA. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction. Am J Hematol 2004;77:187-193.

  5. Key NS. Inhibitors in congenital coagulation disorders. Br J Haematol 2004;127:379-391.

  6. Oldenburg J, Tuddenham E. Genetic basis of inhibitor development in severe haemophilia A and B., En: Rodríguez-Merchan EC, Lee CA, editors. Inhibitors in patients with haemophilia. 1st edition. Oxford: Blackwell Publishing; 2002.

  7. Yee TT, Lee CA. Oral immune tolerance induction to factor VIII via breast milk, a possibility? Haemophilia 2000; 6: 591.

  8. Knobe, KE, Tengborn LI, Petrini P, Ljung RCR. Breastfeeding does not influence the development of inhibitors in hemophilia. Haemophilia 2002;8: 657-659.

  9. Lorenzo JI, Lopez A, Altisent C, Aznar JA. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001;113: 600-603.

  10. van der Bom JG, Mauser-Bunschoten EP, Fischer K, van den Berg HM. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost 2003; 89: 475-479.

  11. Srivastava A. WFH treatment guidelines work group. Guidelines for the management of Hemophilia. World Federation of Hemophilia; 2005. Available at: http://www.wfh.org/Content_ Documents/Other_Publications/Guidelines_Mng_ Hemophilia. pdf. Accessed August 1st, 2005.

  12. Dimichele D, Rivard G, Hay C, Antunes S. Inhibitors in haemophilia: clinical aspects. Haemophilia 2004;10(Suppl.4):140-145.

  13. Luu H and Ewenstein B. FEIBA saqfety profile in multiples modes of clinical and home-therapy application. Haemophilia 2004; 10(suppl.2): 10-16.

  14. RodrÍguez-Merchan EC, Rossino A. Literature review of surgerie management in inhibitor patients. Haemophilia 2004;10(suppl. 2):22-29.

  15. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-890.

  16. Siddiqui MA and Scott LJ. Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital and acquired haemophilia and other congenital bleeding disorders. Drugs 2005; 65: 1161-1177.




2020     |     www.medigraphic.com